

# Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma (terminated appraisal)

Technology appraisal guidance

Published: 27 October 2010

[www.nice.org.uk/guidance/ta207](https://www.nice.org.uk/guidance/ta207)

# Contents

Advice.....	3
Information.....	3

## Advice

NICE is unable to make a recommendation about the use in the NHS of temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma. This is because Wyeth did not provide an evidence submission. They consider that, given the rarity of the condition, the complex clinical management of mantle cell lymphoma and the large number of comparator regimens used in the single randomised clinical trial, an adequate assessment of the clinical and cost effectiveness of temsirolimus would not be possible.

## Information

If NHS organisations wish to consider temsirolimus for this indication, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-6606-6